Stock Screener App

Gratuito - Play StoreApp Store

Installare Installare

Dow:

Nasdaq:

S&P 500:

QURE

$24.831.86%-0.47

Dopo l'orario di chiusura: 26.50+1.67 +6.73%

Uniqure Nv (QURE)

Date: O: H: L: C: Vol:

Uniqure Nv Borsa (QURE) Ultime notizie

QURE Assumes Buy Rating by UBS -- Price Target Raised to $48 - GuruFocus

UBS Adjusts Price Target on uniQure to $48 From $27, Maintains Buy Rating - marketscreener.com

uniQure: The Market Graded The Wrong Exam (NASDAQ:QURE) - Seeking Alpha

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT - GlobeNewswire Inc.

uniQure NV (UQ1.SG) Analyst Insights, Price Targets & Recommendations - Yahoo Finance - Yahoo! Finance Canada

uniQure N.V. (QURE) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE) - Simply Wall Street

UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop - Business Wire

uniQure N.V. (QURE) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review

UniQure Shares Fall After Barclays Downgrade - marketscreener.com

Barclays Downgrades UniQure to Equal Weight From Overweight - Moomoo

Uniqure N.v Stock Price Forecast. Should You Buy QURE? - StockInvest.us

Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy - STAT

$uniQure NV (QURE.US)$ - Moomoo

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire Inc.

uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update - Seeking Alpha

uniQure Plunges on Additional Data From Huntington's Disease Study - Zacks Investment Research

uniQure Plunges on Additional Data From Huntington's Disease Study - Yahoo Finance

uniQure Stock Plunges On 4-Year Data, But The Approval Path Is Intact (Rating Upgrade) - Seeking Alpha

EBITDA of uniQure N.V. – HAN:UQ1 - TradingView

Return on invested capital % of uniQure N.V. – HAN:UQ1 - TradingView

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - Morningstar

Four-year data raise durability questions for uniQure’s Huntington gene therapy - biocentury.com

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - PR Newswire

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - The Transylvania Times

uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish (QURE) - Seeking Alpha

uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression Slowing - Slideshow (NASDAQ:QURE) 2026-09-29 - Seeking Alpha

QURE Investor Alert: uniQure Securities Investigation - Kehoe Law Firm, P.C. - GlobeNewswire Inc.

Why Is uniQure Stock Sinking on Tuesday? - benzinga.com

Why Is uniQure Stock Sinking on Tuesday? - Yahoo Finance

uniQure Highlights Long-Term AMT-130 Huntington’s Data - TipRanks

uniQure Shares Fall 64% After 48-Month AMT-130 Huntington’s Disease Trial Update - finance.yahoo.com

ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update - finance.yahoo.com

uniQure: 80% Slowing on Huntington's Score at 3 Years - Stock Titan

QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntington’s Disease Data – Here’s What Investors Need To Know - finance.yahoo.com

uniQure plunges 65% as 48-month Huntington’s gene therapy data misses key stat - finance.yahoo.com

uniQure posts new data for Huntington’s disease drug (QURE) - Seeking Alpha

Why is uniQure stock collapsing today? - Investing.com

uniQure Announces Additional Data from Ongoing Phase I/II - globenewswire.com

UniQure’s gene therapy continues to slow Huntington’s progression after four years - STAT

UniQure Sinks After Worse-Than-Expected Huntington’s Results - Bloomberg.com

uniQure (NasdaqGS:QURE) Stock Forecast & Analyst Predictions - Simply Wall Street

uniQure stock falls 10.38 percent as cash reaches USD 810.3 million - AD HOC NEWS

Why is uniQure stock sliding today? - Investing.com

QURE Stock Just Shot Up 8% - uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits

QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits

uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com

UniQure N.V. (QURE) Stock Analysis: A Biotech Powerhouse With A 56% Upside Potential - DirectorsTalk Interviews

What to expect from UniQure’s upcoming Huntington’s gene therapy readout - STAT

Simile a QURE

NTLA$12.475.74%

STOK$26.290.23%

MAZE$31.481.41%

REPL$17.611.27%

KLRA$12.864.10%